白藜芦醇保健品治疗高度复杂性近视的有效性和可行性

N. Ulianova, K. M. Hutsaliuk
{"title":"白藜芦醇保健品治疗高度复杂性近视的有效性和可行性","authors":"N. Ulianova, K. M. Hutsaliuk","doi":"10.30702/ophthalmology30062021-13.2.06-13/617.753.29","DOIUrl":null,"url":null,"abstract":"The paper is dedicated to the study of the efficiency of nutraceutical with resveratrol and vitamins and antioxidants of AREDS (Age-Related Eye Disease Studies) formula in patients with high myopia. Seventy-five patients (150 eyes) with high axial myopia (–7.0 to –20.0 diopters) and chorioretinal dystrophy were examined. Group I included 21 patients (42 eyes) who received conservative nootropic and metabolic therapy; group II included 34 patients (68 eyes) who received a nutraceutical containing 60 mg of trans-resveratrol combined with components of AREDS formula, omega-3 fatty acid and vitamin D (Resvega®Forte) at the end of nootropic and metabolic therapy; group III included 20 patients (40 eyes) who did not receive conservative treatment. The effectiveness of treatment was evaluated based on maximal corrected visual acuity (MCVA), phosphene threshold (PT) and the findings of optical coherence tomography of the macula (foveal thickness (FT) and subfoveal choroidal thickness (SCT)) every 6 months before and after treatment. In patients of group II, the MCVA increase during the first year was 29.8% versus baseline (p=0.005), and the achieved therapeutic effect was maintained until the end of the second year of the follow-up period. The patients of group III showed MCVA decrease by 19.1% after 24 months from the start of the follow-up period. Despite the absence of statistical difference in baseline MCVA in all the groups, MCVA in patients of group III was lower than that in patients of group II after 12 months and lower than that in patients of group I (p˂0.0002) after 24 months. There was a 4.7 % increase in FT in patients of group III versus baseline (p˂0.05). The patients of group III showed a 34.4% decrease in SCT versus baseline (p<0.05). Thus, the use of nutraceuticals with resveratrol and antioxidants of AREDS formula in the comprehensive treatment of patients with myopic chorioretinal dystrophies allows to achieve good functional results with stable foveal thickness without signs of myopic choroidal vascularization and preservation of subfoveal choroidal thickness.","PeriodicalId":196817,"journal":{"name":"Ukrainian journal Ophthalmology","volume":"440 1","pages":"0"},"PeriodicalIF":0.0000,"publicationDate":"2021-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Efficiency and Feasibility of Using Resveratrol Nutraceuticals in Patients with High Complicated Myopia\",\"authors\":\"N. Ulianova, K. M. Hutsaliuk\",\"doi\":\"10.30702/ophthalmology30062021-13.2.06-13/617.753.29\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"The paper is dedicated to the study of the efficiency of nutraceutical with resveratrol and vitamins and antioxidants of AREDS (Age-Related Eye Disease Studies) formula in patients with high myopia. Seventy-five patients (150 eyes) with high axial myopia (–7.0 to –20.0 diopters) and chorioretinal dystrophy were examined. Group I included 21 patients (42 eyes) who received conservative nootropic and metabolic therapy; group II included 34 patients (68 eyes) who received a nutraceutical containing 60 mg of trans-resveratrol combined with components of AREDS formula, omega-3 fatty acid and vitamin D (Resvega®Forte) at the end of nootropic and metabolic therapy; group III included 20 patients (40 eyes) who did not receive conservative treatment. The effectiveness of treatment was evaluated based on maximal corrected visual acuity (MCVA), phosphene threshold (PT) and the findings of optical coherence tomography of the macula (foveal thickness (FT) and subfoveal choroidal thickness (SCT)) every 6 months before and after treatment. In patients of group II, the MCVA increase during the first year was 29.8% versus baseline (p=0.005), and the achieved therapeutic effect was maintained until the end of the second year of the follow-up period. The patients of group III showed MCVA decrease by 19.1% after 24 months from the start of the follow-up period. Despite the absence of statistical difference in baseline MCVA in all the groups, MCVA in patients of group III was lower than that in patients of group II after 12 months and lower than that in patients of group I (p˂0.0002) after 24 months. There was a 4.7 % increase in FT in patients of group III versus baseline (p˂0.05). The patients of group III showed a 34.4% decrease in SCT versus baseline (p<0.05). Thus, the use of nutraceuticals with resveratrol and antioxidants of AREDS formula in the comprehensive treatment of patients with myopic chorioretinal dystrophies allows to achieve good functional results with stable foveal thickness without signs of myopic choroidal vascularization and preservation of subfoveal choroidal thickness.\",\"PeriodicalId\":196817,\"journal\":{\"name\":\"Ukrainian journal Ophthalmology\",\"volume\":\"440 1\",\"pages\":\"0\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2021-06-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Ukrainian journal Ophthalmology\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.30702/ophthalmology30062021-13.2.06-13/617.753.29\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ukrainian journal Ophthalmology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.30702/ophthalmology30062021-13.2.06-13/617.753.29","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

摘要

本文研究了含白藜芦醇和AREDS (Age-Related Eye Disease Studies)配方中维生素和抗氧化剂的营养保健品对高度近视患者的疗效。本文对高度轴性近视(-7.0 ~ -20.0屈光度)伴绒毛膜视网膜营养不良患者75例(150眼)进行了检查。第一组包括21例患者(42只眼),接受保守促智和代谢治疗;II组包括34名患者(68只眼睛),他们在促智和代谢治疗结束时接受含有60毫克反式白藜芦醇联合AREDS配方成分、omega-3脂肪酸和维生素D (Resvega®Forte)的营养保健品;III组20例(40只眼)未接受保守治疗。根据治疗前后每6个月的最大矫正视力(MCVA)、磷光阈值(PT)和黄斑光学相干断层扫描(中央凹厚度(FT)和中央凹下脉络膜厚度(SCT))结果评估治疗效果。在II组患者中,第一年的MCVA比基线增加了29.8% (p=0.005),并且达到的治疗效果一直保持到随访期的第二年结束。III组患者随访24个月后MCVA下降19.1%。各组患者基线MCVA无统计学差异,但12个月后,III组患者的MCVA低于II组患者,24个月后,III组患者的MCVA低于I组患者(p小于0.0002)。与基线相比,III组患者的FT增加了4.7% (p小于0.05)。III组患者SCT较基线下降34.4% (p<0.05)。因此,使用含有白藜芦醇和AREDS配方抗氧化剂的营养品综合治疗近视性绒毛膜视网膜营养不良患者,可以获得良好的功能效果,稳定的中央凹厚度,没有近视的脉络膜血管形成的迹象,并保留了中央凹下的脉络膜厚度。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Efficiency and Feasibility of Using Resveratrol Nutraceuticals in Patients with High Complicated Myopia
The paper is dedicated to the study of the efficiency of nutraceutical with resveratrol and vitamins and antioxidants of AREDS (Age-Related Eye Disease Studies) formula in patients with high myopia. Seventy-five patients (150 eyes) with high axial myopia (–7.0 to –20.0 diopters) and chorioretinal dystrophy were examined. Group I included 21 patients (42 eyes) who received conservative nootropic and metabolic therapy; group II included 34 patients (68 eyes) who received a nutraceutical containing 60 mg of trans-resveratrol combined with components of AREDS formula, omega-3 fatty acid and vitamin D (Resvega®Forte) at the end of nootropic and metabolic therapy; group III included 20 patients (40 eyes) who did not receive conservative treatment. The effectiveness of treatment was evaluated based on maximal corrected visual acuity (MCVA), phosphene threshold (PT) and the findings of optical coherence tomography of the macula (foveal thickness (FT) and subfoveal choroidal thickness (SCT)) every 6 months before and after treatment. In patients of group II, the MCVA increase during the first year was 29.8% versus baseline (p=0.005), and the achieved therapeutic effect was maintained until the end of the second year of the follow-up period. The patients of group III showed MCVA decrease by 19.1% after 24 months from the start of the follow-up period. Despite the absence of statistical difference in baseline MCVA in all the groups, MCVA in patients of group III was lower than that in patients of group II after 12 months and lower than that in patients of group I (p˂0.0002) after 24 months. There was a 4.7 % increase in FT in patients of group III versus baseline (p˂0.05). The patients of group III showed a 34.4% decrease in SCT versus baseline (p<0.05). Thus, the use of nutraceuticals with resveratrol and antioxidants of AREDS formula in the comprehensive treatment of patients with myopic chorioretinal dystrophies allows to achieve good functional results with stable foveal thickness without signs of myopic choroidal vascularization and preservation of subfoveal choroidal thickness.
求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信